Difference between revisions of "Talk:Oligomycin"
From Bioblast
(Created page with "== ETS capacity after inhibition by Omy == * We are having problems recovering full activity with FCCP after oligomycin, and although diluting Omy to low but effective concentra...") |
|||
| Line 3: | Line 3: | ||
* We are having problems recovering full activity with FCCP after oligomycin, and although diluting Omy to low but effective concentration help, it does not solve the problem. Thus, we are considering buying the more expensive forms of Omy. (2013-02-21; [[Crawford DL|Doug Crawford]], University of Miami, US) | * We are having problems recovering full activity with FCCP after oligomycin, and although diluting Omy to low but effective concentration help, it does not solve the problem. Thus, we are considering buying the more expensive forms of Omy. (2013-02-21; [[Crawford DL|Doug Crawford]], University of Miami, US) | ||
* We are facing the same problems during recent years, and are worried about what is going wrong. Whereas pathologically stressed mitos with a latent injury do respond to the additional Omy induced stress by loosing ETS capacity, the controls gave us recently the same problems, which we consider as artefacts for unknown reasons. Quality control of formerly functional chemicals becomes an increasingly worrying issue. (2013-02-21; [[Gnaiger E|Erich Gnaiger]], Medical University Innsbruck, AT) | * We are facing the same problems during recent years, and are worried about what is going wrong. Whereas pathologically stressed mitos with a latent injury do respond to the additional Omy induced stress by loosing ETS capacity, the controls gave us recently the same problems, which we consider as artefacts for unknown reasons. Quality control of formerly functional chemicals becomes an increasingly worrying issue. (2013-02-21; [[Gnaiger E|Erich Gnaiger]], Medical University Innsbruck, AT) | ||
== Oligomycin page accessed == | |||
[[Oligomycin]] has been accessed more than | |||
:* 5,000 times (2013-10-17) | |||
Revision as of 23:54, 17 October 2013
ETS capacity after inhibition by Omy
- We are having problems recovering full activity with FCCP after oligomycin, and although diluting Omy to low but effective concentration help, it does not solve the problem. Thus, we are considering buying the more expensive forms of Omy. (2013-02-21; Doug Crawford, University of Miami, US)
- We are facing the same problems during recent years, and are worried about what is going wrong. Whereas pathologically stressed mitos with a latent injury do respond to the additional Omy induced stress by loosing ETS capacity, the controls gave us recently the same problems, which we consider as artefacts for unknown reasons. Quality control of formerly functional chemicals becomes an increasingly worrying issue. (2013-02-21; Erich Gnaiger, Medical University Innsbruck, AT)
Oligomycin page accessed
Oligomycin has been accessed more than
- 5,000 times (2013-10-17)
